Sirius Neosight is developing technology to measure membrane fluidity, a methodology for the discrimination and purification of Circulating Tumour Cells (CTCs) present in the blood stream, aiming to revolutionize early detection of cancer recurrences and personalized therapies
Sirius Neosight is developing technology to measure membrane fluidity, a methodology for the discrimination and purification of Circulating Tumour Cells (CTCs) present in the blood stream, aiming to revolutionize early detection of cancer recurrences and personalized therapies.